Researchers say they may have discovered a new drug for the treatment of metastatic melanoma, one that uses the patient’s own tumor cells to customize the therapy. The findings are published in the March issue of the journal Clinical Cancer Research.

The drug is sunitinib, which has already been approved by the FDA for the treatment of kidney cancer and gastrointestinal stromal cancer. In this Phase II clinical trial sunitinib proved effective against rare forms of melanoma that occur on parts of the body that the sun doesn’t hit — such as the mucosal surfaces of the mouth, the soles of the feet, and the palms of the hand.

Read the entire article –>

If you enjoyed this post, make sure you subscribe to my RSS feed!